| Abstrakt: |
A recent study conducted by researchers from the National Institute of Technology in Durgapur, India, explores the development of a new drug delivery platform for the cancer drug 6-thioguanine (6-TG). The researchers have successfully conjugated 6-TG to gold nanoclusters, creating a nanoconjugate called AuNC@BSA-TG. This nanoconjugate exhibits efficient drug loading, release in the presence of cancer cell environments, and synergistic amplification of oxidative stress. The study demonstrates the potential of this combinatorial approach for treating challenging KRAS-mutated cancers. This research has been published in the Journal of Drug Delivery Science and Technology. [Extracted from the article] |
